Handheld ECG for Measurement of QTc interval Receives FDA Clearance

AliveCor's KardiaMobile 6L device which can calculate patients' QTc interval recently has received FDA clearance.;

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2021-07-12 03:30 GMT | Update On 2021-07-12 05:51 GMT

The US Food and Drug Administration has given clearance to KardiaMobile 6L device for calculating patients' QTc interrval by healthcare professionals.

AliveCor, a medical device and artificial intelligence company that sells ECG hardware and software for consumer mobile devices has recently received the clearance .

The QT interval on an electocardiogram is the time from the beginning of the QRS complex, representing ventricular depolarization, to the end of the T wave, resulting from ventricular repolarization. Due to the effects of heart rate, the corrected QT interval (QTc) is frequently used.

These developments will enable healthcare professionals to use the KardiaMobile 6L device to obtain an ECG which they can use to manually measure their patients' QT interval. AliveCor claims that this device is fast, easy, and convenient as it can be done by the healthcare professional in the office and even remotely by the patient. KardiaMobile 6L is the first and only hand-held ECG device that is FDA cleared for measurement of QTc.

QT prolongation can stem from congenital long QT syndrome, many disease states or electrolyte abnormalities. Patients with a prolonged QTc are at greater risk for their hearts to go into a potentially dangerous arrhythmia. QT prolongation can also be a potential side effect of more than 100 FDA-approved medications including certain antiarrhythmic medicines, cancer therapies, antifungals, antipsychotics, antidepressants, antibiotics, multiple sclerosis (MS) medications, and opioids etc.

Medicines known to cause QT prolongation are commonly prescribed by healthcare professionals, who may not have ECG capabilities readily available. Some physicians view QT prolongation as a barrier to prescribing these potentially life-saving medicines.

"Patient safety is paramount, and this is why we are proud to offer physicians the ability to monitor QTc through the convenience and quality of our device. It is our hope that this important FDA clearance will help healthcare professionals identify and save patients from this potentially life-threatening condition," Priya Albani, CEO of AliveCor told mediapersons.

Article Source : Press release

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Dr Kartikeya Kohli

Dr Kartikeya Kohli is an Internal Medicine Consultant at Sitaram Bhartia Hospital in Delhi with super speciality training in Nephrology. He has worked with various eminent hospitals like Indraprastha Apollo Hospital, Sir Gangaram Hospital. He holds an MBBS from Kasturba Medical College Manipal, DNB Internal Medicine, Post Graduate Diploma in Clinical Research and Business Development, Fellow DNB Nephrology, MRCP and ECFMG Certification. He has been closely associated with India Medical Association South Delhi Branch and Delhi Medical Association and has been organising continuing medical education programs on their behalf from time to time. Further he has been contributing medical articles for their newsletters as well. He is also associated with electronic media and TV for conduction and presentation of health programs. He has been associated with Medical Dialogues for last 3 years and contributing articles on regular basis.

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Handheld ECG for Measurement of QTc interval Receives FDA Clearance

AliveCor's KardiaMobile 6L device which can calculate patients' QTc interval recently has received FDA clearance.;

Similar News

Orforglipron Shows Significant Weight Loss and Heart Health Benefits in Phase 3 Trial

SGLT2 Inhibitors Fail to Impact MI Severity or Outcomes in T2DM Patients: Study

DMARD Use and Rheumatoid Arthritis Raise Mortality in Bronchiectasis Patients: Study Shows

Sanofi Consumer Healthcare India Limited launches Allegra-D in India: Non-Drowsy Allergy Relief with Nasal Decongestion

FDA Approves Inclisiran as First-Line LDL-C Treatment Without Statins

How does metformin lower blood sugar?

Vitiligo Causally Linked to Rheumatoid Arthritis, Type 1 Diabetes, and Alopecia Areata: Study

Modified open anterior mesh repair Effective for Groin Hernias in Women in Low-Resource Settings: JAMA